Efficacy and Safety of Lenalidomide (LEN) Plus Low-Dose Dexamethasone (DEX; Rd) in Chinese Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) According to Disease Stage (International Staging System [ISS]): Results From the MM-021 Trial and MM-024 Extended Access Program (EAP)

J Hou,D Wu,F Meng,X Ke,J Mei,J Zhang,Z Cai,J Jin,D.B Zhou,X Du,F Chen,X Li,D Demarco,L Yu

doi:10.1016/j.clml.2015.07.599

Efficacy and Safety of Lenalidomide (LEN) Plus Low-Dose Dexamethasone (DEX; Rd) in Chinese Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) According to Disease Stage (International Staging System [ISS]): Results From the MM-021 Trial and MM-024 Extended Access Program (EAP)

J Hou, D Wu + Show 12 more

https://doi.org/10.1016/j.clml.2015.07.599

Copy DOI

Journal: Clinical Lymphoma & Myeloma

Publication Date: Sep 1, 2015

Affiliation: Shanghai Changzheng Hospital, Soochow University, Peking University, Peking University Third Hospital, First Affiliated Hospital Zhejiang University, Guangdong General Hospital, Xiangya Hospital Central South University, Central South University, Chinese PLA General Hospital

#ISS Stage #Daratumumab + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Efficacy and Safety of Lenalidomide (LEN) Plus Low-Dose Dexamethasone (DEX; Rd) in Chinese Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) According to Disease Stage (International Staging System [ISS]): Results From the MM-021 Trial and MM-024 Extended Access Program (EAP)

Full Text